Levi & Korsinsky Opens Investigation Into Zevra Therapeutics Selloff

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued its adverse opinion before the opening bell, marking the stock's most significant single-day percentage drop in over five years. While Zevra Therapeutics has stated its intent to request a re-examination of the decision and maintain its global Expanded Access Program for the drug, the market reaction has drawn the attention of shareholder rights attorneys.

Levi & Korsinsky is currently evaluating whether the company provided misleading information to investors concerning the regulatory outlook for arimoclomol, marketed as Meplyffa, prior to the negative CHMP ruling. The investigation seeks to determine if shareholders are entitled to pursue claims for losses incurred during the subsequent selloff. Participation in the review process is open to investors regardless of their current holding status or geographic location, provided they purchased securities on U.S. exchanges. Legal counsel typically handles such matters on a contingency basis, meaning no upfront costs are required for those submitting loss documentation.